VEGFA and renal cell carcinoma: The treatment of advanced and metastatic RCC is difficult, based on the combination of several agents, targeting multiple receptor tyrosine kinases, including growth-factor receptors such as vascular endothelial growth factor receptor (VEGFR), or directly targeting VEGF, often in combination with immune checkpoint inhibitors (ICIs) [8,9,10,11,12,13].